PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27657380-8	2016	Apoptosis was associated with increased hallmarks of ER stress and activation of UPR sensors and was mediated by dephosphorylation of the AKT, MAPK/ERK, and STAT3 pathways.The combination of romidepsin and lenalidomide shows promise as a possible treatment for T-cell lymphoma.	Lenalidomide	206-218	signal transducer and activator of transcription 3	Homo sapiens	157-162	
30741931-0	2019	Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.	Lenalidomide	18-30	signal transducer and activator of transcription 3	Homo sapiens	133-138	
30741931-7	2019	Inhibition of STAT3 with a selective compound (PB-1-102) re-sensitized XG1LenRes to lenalidomide.	Lenalidomide	84-96	signal transducer and activator of transcription 3	Homo sapiens	14-19	
29379494-0	2017	The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide.	Lenalidomide	121-133	signal transducer and activator of transcription 3	Homo sapiens	10-15	
29379494-5	2017	Furthermore, experiments to assess the role of lenalidomide, an immunomodulatory agent with direct antitumor effect as well as pleiotropic activity on the immune system, showed that this agent prevents a CXCL12-induced increase in p-S727-STAT3 and the IL-10 response by CLL cells.	Lenalidomide	47-59	signal transducer and activator of transcription 3	Homo sapiens	238-243	
29379494-6	2017	Lenalidomide also suppressed IL-10-induced Y705-STAT3 phosphorylation in healthy T cells, thus reversing CLL-induced T-cell dysfunction.	Lenalidomide	0-12	signal transducer and activator of transcription 3	Homo sapiens	48-53	
29379494-8	2017	Lenalidomide appears to be able to reverse CLL-induced immunosuppression through including abrogation of the CXCL12-CXCR4-S727-STAT3-mediated IL-10 response by CLL cells and prevention of IL-10-induced phosphorylation of Y705-STAT3 in T cells.	Lenalidomide	0-12	signal transducer and activator of transcription 3	Homo sapiens	127-132	
29379494-8	2017	Lenalidomide appears to be able to reverse CLL-induced immunosuppression through including abrogation of the CXCL12-CXCR4-S727-STAT3-mediated IL-10 response by CLL cells and prevention of IL-10-induced phosphorylation of Y705-STAT3 in T cells.	Lenalidomide	0-12	signal transducer and activator of transcription 3	Homo sapiens	226-231	
28529032-0	2017	Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis.	Lenalidomide	28-40	signal transducer and activator of transcription 3	Homo sapiens	128-133	
28529032-2	2017	Cereblon is probably targeted by both lenalidomide and dexamethasone, which leads to synergistic cytotoxicity in MCL by inhibiting the interleukin-6/signal transducer and activator of transcription 3 (IL-6/STAT3), phosphatidylinositol 3-kinase (PI3K)/AKT and AKT2/Forkhead box O3 (FOXO3A)/BCL2-like 11 (BIM) pathways.	Lenalidomide	38-50	signal transducer and activator of transcription 3	Homo sapiens	206-211	
34455369-4	2021	In three of four tested HTLV-1-infected cell lines, the cells treated with lenalidomide or pomalidomide exhibited mild growth suppression without apoptosis, which was associated with decreased IRF4, c-Myc, and phosphorylated STAT3 levels as well as enhanced SOCS3 expression.	Lenalidomide	75-87	signal transducer and activator of transcription 3	Homo sapiens	225-230